168 related articles for article (PubMed ID: 27736728)
21. Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells.
Sturlan S; Baumgartner M; Roth E; Bachleitner-Hofmann T
Blood; 2003 Jun; 101(12):4990-7. PubMed ID: 12609832
[TBL] [Abstract][Full Text] [Related]
22. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation.
Yuksel S; Saydam G; Uslu R; Sanli UA; Terzioglu E; Buyukececi F; Omay SB
Leuk Res; 2002 Apr; 26(4):391-8. PubMed ID: 11839383
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effect of arsenic trioxide in human K562 and K562/ADM cells by autophagy.
Cheng J; Wei HL; Chen J; Xie B
Toxicol Mech Methods; 2012 Sep; 22(7):512-9. PubMed ID: 22519831
[TBL] [Abstract][Full Text] [Related]
24. Multidrug resistance protein 1 (ABCC1) confers resistance to arsenic compounds in human myeloid leukemic HL-60 cells.
Xu S; Zhang YF; Carew MW; Hao WH; Loo JF; Naranmandura H; Le XC
Arch Toxicol; 2013 Jun; 87(6):1013-23. PubMed ID: 23052202
[TBL] [Abstract][Full Text] [Related]
25. Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.
Zhao H; Guo W; Peng C; Ji T; Lu X
Mol Biol Rep; 2010 Jun; 37(5):2509-15. PubMed ID: 19701692
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds.
Glienke W; Chow KU; Bauer N; Bergmann L
Leuk Lymphoma; 2006 Aug; 47(8):1629-38. PubMed ID: 16966277
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines.
Zhao YY; Yu L; Liu BL; He XJ; Zhang BY
Mol Med Rep; 2015 Nov; 12(5):7335-43. PubMed ID: 26459009
[TBL] [Abstract][Full Text] [Related]
28. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
[TBL] [Abstract][Full Text] [Related]
29. [Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM].
Cai X; Chen FY; Han JY; Gu CH; Zhong H; Ouyang RR
Ai Zheng; 2004 Dec; 23(12):1611-5. PubMed ID: 15601547
[TBL] [Abstract][Full Text] [Related]
30. [Apoptosis of the adriamycin-resistant leukemia cell line induced by the recombinant mutant human TNF-related apoptosis-inducing ligand combined with arsenic trioxide].
Wang YR; Wen SP; Wang FX; Wen L; Yang BY; Yang JC; Zhang XJ; Yang SF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1055-9. PubMed ID: 18928594
[TBL] [Abstract][Full Text] [Related]
31. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
Mukai M; Che XF; Furukawa T; Sumizawa T; Aoki S; Ren XQ; Haraguchi M; Sugimoto Y; Kobayashi M; Takamatsu H; Akiyama S
Cancer Sci; 2003 Jun; 94(6):557-63. PubMed ID: 12824882
[TBL] [Abstract][Full Text] [Related]
32. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Lee C; Lin Y; Huang M; Lin C; Liu C; Chow J; Liu HE
Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
[TBL] [Abstract][Full Text] [Related]
33. Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line.
Guo-Bao W; Xiao-Qin C; Qi-Rong G; Jie L; Gui-Nan L; Yue L
Leuk Lymphoma; 2010 Jun; 51(6):1090-7. PubMed ID: 20470221
[TBL] [Abstract][Full Text] [Related]
34. The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.
Salerno M; Petroutsa M; Garnier-Suillerot A
J Bioenerg Biomembr; 2002 Apr; 34(2):135-45. PubMed ID: 12018890
[TBL] [Abstract][Full Text] [Related]
35. Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
Peng CY; Jiang J; Zheng HT; Liu XS
Leuk Lymphoma; 2010 Feb; 51(2):297-303. PubMed ID: 20038232
[TBL] [Abstract][Full Text] [Related]
36. [Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl].
Chen L; Wang JM; Xu XP; Gao L; Fei XH; Lou JW; Huang ZX
Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):535-8. PubMed ID: 15555283
[TBL] [Abstract][Full Text] [Related]
37. Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system.
Lösler S; Schlief S; Kneifel C; Thiel E; Schrezenmeier H; Rojewski MT
Ann Hematol; 2009 Nov; 88(11):1047-58. PubMed ID: 19301004
[TBL] [Abstract][Full Text] [Related]
38. The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells.
Chen X; Zhang M; Liu LX
Oncol Rep; 2009 Jul; 22(1):73-80. PubMed ID: 19513507
[TBL] [Abstract][Full Text] [Related]
39. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.
Matulis SM; Morales AA; Yehiayan L; Croutch C; Gutman D; Cai Y; Lee KP; Boise LH
Mol Cancer Ther; 2009 May; 8(5):1197-206. PubMed ID: 19417148
[TBL] [Abstract][Full Text] [Related]
40. The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status.
Huang MJ; Hsieh RK; Lin CP; Chang IY; Liu HJ
Leuk Lymphoma; 2002 Nov; 43(11):2191-9. PubMed ID: 12533046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
